Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Date publication

mai 2018

Journal

Neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29695592

Résumé

To describe clinical and radiologic features associated with myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in a large French nationwide adult cohort, to assess baseline prognostic features of MOG-Ab-associated diseases after a first acute demyelinating syndrome, and to evaluate the clinical value of MOG-Ab longitudinal analysis.

Référence

Neurology. 2018 May 22;90(21):e1858-e1869